We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Schizophrenia Drug Kills Tuberculosis Bacteria

By Biotechdaily staff writers
Posted on 23 Mar 2005
Researchers have found that phenothiazine, a drug used to treat schizophrenia, kills the bacteria that cause tuberculosis (TB) through the inhibition of the bacterial enzyme type II NADH dehydrogenase.

In 1993 the World Health Organization declared TB a global health emergency; approximately one third of the world's population is infected, and an estimated three million die from the disease each year. More...
Especially alarming has been the spread of drug-resistant strains of TB. By the late 1990s, scientific experts and international health officials warned that drug-resistant strains were spreading faster than had been anticipated. Some believe that unless major new treatment strategies are initiated in source countries, drug-resistant TB will eventually become epidemic even in areas with good control programs, such as Europe and the United States.

In the current study, investigators at the University of Pennsylvania School of Medicine (Philadelphia, USA) used the anti-schizophrenia drug phenothiazine to treat Mycobacterium tuberculosis bacteria growing in culture and to treat mice that had been infected with the bacteria. They reported in the March 14, 2005, online edition of the Proceedings of the [U.S.] National Academy of Sciences that several phenothiazine analogs were potent killers of tuberculosis bacteria in culture and suppressed bacterial growth in a mouse model of acute infection. The target of the drug was found to be the enzyme type II NADH dehydrogenase.

"What we have now is a new target in TB,” said senior author Dr. Harvey Rubin, professor of medicine at the University of Pennsylvania School of Medicine. "We have been able to find at least the beginnings of a class of compounds that we can start working with and that we know is biochemically active against the TB bacteria in culture and in small animals. We discovered that if you inhibit the very first enzyme in the chain, you inhibit everything else downstream and eventually the bacteria die.”



Related Links:
University of Pennsylvania School of Medicine

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
All-in-One Molecular System
AIO M160
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The findings indicate that measuring Lp(a) may help identify individuals at increased lifetime risk of atherosclerosis beyond conventional cardiovascular risk factors. (Image Credit: Adobe Stock)

Elevated Lipoprotein(a) Linked to Long-Term Progression of Carotid Atherosclerosis

Lipoprotein(a), or Lp(a), is a genetically determined blood lipid and an important risk factor for cardiovascular disease. Its relationship to long-term carotid atherosclerosis has remained unclear, particularly... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.